|Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial|
G Theron, L Zijenah, D Chanda, P Clowes, A Rachow, M Lesosky, W Bara, ...
The Lancet 383 (9915), 424-435, 2014
|Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting|
G Theron, J Peter, R van Zyl-Smit, H Mishra, E Streicher, S Murray, ...
American journal of respiratory and critical care medicine 184 (1), 132-40, 2011
|The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis|
K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ...
The lancet Respiratory medicine 5 (4), 291-360, 2017
|Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis|
K Dheda, T Gumbo, NR Gandhi, M Murray, G Theron, Z Udwadia, ...
The lancet Respiratory medicine 2 (4), 321-338, 2014
|What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?|
A Pooran, E Pieterson, M Davids, G Theron, K Dheda
PloS one 8 (1), 2013
|Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study|
VB Patel, G Theron, L Lenders, B Matinyena, C Connolly, R Singh, ...
PLoS medicine 10 (10), 2013
|Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic …|
JG Peter, LS Zijenah, D Chanda, P Clowes, M Lesosky, P Gina, N Mehta, ...
The Lancet 387 (10024), 1187-1197, 2016
|Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?|
G Theron, J Peter, D Dowdy, I Langley, SB Squire, K Dheda
The Lancet infectious diseases 14 (6), 527-532, 2014
|Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients|
JG Peter, G Theron, R van Zyl-Smit, A Haripersad, L Mottay, S Kraus, ...
European respiratory journal 40 (5), 1211-1220, 2012
|Point‐of‐care diagnosis of tuberculosis: Past, present and future|
K Dheda, M Ruhwald, G Theron, J Peter, WC Yam
Respirology 18 (2), 217-232, 2013
|The diagnostic accuracy of the GenoTypeŽ MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs|
G Theron, J Peter, M Richardson, M Barnard, S Donegan, R Warren, ...
The Cochrane database of systematic reviews, 4, 2014
|The Diagnostic Accuracy of Urine-Based Xpert MTB/RIF in HIV-Infected Hospitalized Patients Who Are Smear-Negative or Sputum Scarce|
JG Peter, G Theron, TE Muchinga, U Govender, K Dheda
PLoS ONE 7 (7), e39966, 2012
|Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments|
G Theron, J Peter, G Calligaro, R Meldau, C Hanrahan, H Khalfey, ...
Scientific reports 4, 5658, 2014
|Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid|
G Theron, J Peter, R Meldau, H Khalfey, P Gina, B Matinyena, L Lenders, ...
Thorax 68 (11), 1043-1051, 2013
|Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable …|
K Dheda, JD Limberis, E Pietersen, J Phelan, A Esmail, M Lesosky, ...
The lancet Respiratory medicine 5 (4), 269-281, 2017
|Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden|
RN van Zyl-Smit, A Binder, R Meldau, H Mishra, PL Semple, G Theron, ...
PloS one 6 (12), 2011
|The South African tuberculosis care cascade: estimated losses and methodological challenges|
P Naidoo, G Theron, MX Rangaka, VN Chihota, L Vaughan, ZO Brey, ...
The Journal of infectious diseases 216 (suppl_7), S702-S713, 2017
|Data for action: collection and use of local data to end tuberculosis|
G Theron, HE Jenkins, F Cobelens, I Abubakar, AJ Khan, T Cohen, ...
The Lancet 386 (10010), 2324-2333, 2015
|Do adjunct TB tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?|
G Theron, A Pooran, J Peter, R van Zyl-Smit, HK Mishra, R Meldau, ...
European Respiratory Journal 40 (1), 161-8, 2011
|Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa|
K Shean, E Streicher, E Pieterson, G Symons, R van Zyl Smit, G Theron, ...
PloS one 8 (5), 2013